IP Library Patent Application 17102311
Patent Application
App. No. 17/102,311

TRANSIENT PROTECTION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AGAINST IONIZING RADIATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/102,311
Abstract

This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.

Claims (13)

1 . A method for reducing the effect of ionizing radiation exposure on hematopoietic stem cells and/or progenitor cells (HSPCs) in a human receiving ionizing radiation for the treatment of a CDK4/6 replication independent cancer, the method comprising administering to the human an effective amount of a CDK4/6 inhibitor compound having the structure:

or its pharmaceutically acceptable salt thereof,

wherein the CDK4/6 inhibitor is administered less than about 4 hours prior to receiving ionizing radiation.

2 . The method of claim 1 , wherein the cancer is selected from small cell lung cancer, triple-negative breast cancer, human papilloma virus (HPV)-positive head and neck cancer, retinoblastoma, retinoblastoma protein (Rb)-negative bladder cancer, retinoblastoma protein (Rb)-negative prostate cancer, osteosarcoma, or cervical cancer.

3 . The method of claim 2 , wherein the cancer is small cell lung cancer.

4 . The method of claim 2 , wherein the cancer is triple-negative breast cancer.

5 . The method of claim 2 , wherein the cancer is human papilloma virus (HPV)-positive head and neck cancer.

6 . The method of claim 2 , wherein the cancer is retinoblastoma.

7 . The method of claim 2 , wherein the cancer is retinoblastoma protein (Rb)-negative bladder cancer.

8 . The method of claim 2 , wherein the cancer is retinoblastoma protein (Rb)-negative prostate cancer.

9 . The method of claim 2 , wherein the cancer is osteosarcoma.

10 . The method of claim 2 , wherein the cancer is cervical cancer.

11 . The method of claim 2 , wherein the CDK4/6 inhibitor is administered to the subject prior to exposure to the ionizing radiation such that the compound reaches peak serum levels during exposure to the ionizing radiation.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 055725 FRAME: 0654. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 29, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055748/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055725/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2021
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH
To: G1 THERAPEUTICS, INC.
Reel/Frame 055650/0951 →